Rheumatoid arthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 17
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• AKT 0
• STING 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

24 of 2,478 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, United Kingdom· EU contribution €4,793,228· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Sweden· EU contribution €7,995,375· until Jun 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, United Kingdom· EU contribution €150,000· until Nov 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution €2,499,750· until Apr 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €150,000· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

5 of 35 running projects, newest first. Listed amounts together: €169.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Evaluation of a Connected Interface to Improve the Quality of Life and the Disability of Patient With Rheumatic Diseases

  NCT05417477· University Hospital, Montpellier· Updated 10 Nov 2026

  “Problems encountered with the device used in the study”Registry text, quoted unchanged. Source

• Suspended

  Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

  NCT04530305· University Hospital, Montpellier· Updated 26 Oct 2026

  “Evolution of treatment sequencing for JAK inhibitors”Registry text, quoted unchanged. Source

• Withdrawn

  Cannabichromene Safety in Rheumatoid Arthritis

  NCT07087938· Crystal Lederhos Smith· Updated 23 Sept 2026

  “Study did not begin recruiting participants due to insufficient preclinical evidence resulting in FDA clinical hold.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 20 Jul 2026

  “The study is being closed early due to insufficient participant enrollment across study sites.”Registry text, quoted unchanged. Source

• Withdrawn

  An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)

  NCT07706868· Swedish Orphan Biovitrum· Updated 16 Jul 2026

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis

  NCT02720874· Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center· Updated 2 Jul 2026

  “Terminated due to several programmatic delays such as personnel transitions and departures, challenges to replace them as specified in the protocol, and delays due to COVID-19 pandemic-related institutional closures and clinical research pauses.”Registry text, quoted unchanged. Source

• Terminated

  A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

  NCT06859294· Eli Lilly and Company· Updated 17 Jun 2026

  “The interim analysis data failed to demonstrate the intended treatment effect.”Registry text, quoted unchanged. Source

• Withdrawn

  An Open-label Study of GC012F in Rheumatoid Arthritis.

  NCT07315503· Institute of Hematology & Blood Diseases Hospital, China· Updated 10 Jun 2026

  “Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study”Registry text, quoted unchanged. Source

• Terminated

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 10 Jun 2026

  “The study was closed due to continued enrollment hurdles.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Source

• A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· AstraZeneca· Source

• Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis

  NCT07904754· AbbVie· Source

• A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

  NCT07649265· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis

  NCT07916623· Ege University· Source

• A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

  NCT07363590· Merck Sharp & Dohme LLC· Source

• Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

  NCT07201558· AstraZeneca· Source

• A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)

  NCT07895524· Merck Sharp & Dohme LLC· Source

• COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

  NCT06599658· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis

  NCT05788705· Adel A.Gomaa· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 97
• CRISPR-Cas Systems 1
• Gene Expression Profiling 121
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 52
• Metabolomics 45
• Mass Spectrometry 7
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 58
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 160
• Genome-Wide Association Study 113

• Anti-Neuronal Antibodies in Patients with Sjögren's Syndrome and Acute Cerebellar Ataxia: Two Case Reports.

  Acta Neurol Taiwan, Oct 2026

• Extracapsular and joint-dominant hand and wrist MRI patterns in psoriatic and rheumatoid arthritis: an exploratory case-control study.

  Front Immunol, Oct 2026

• In vivo monitoring of polymorphonuclear myeloid-derived suppressor cells in experimental rheumatoid arthritis.

  Front Immunol, Oct 2026

• Comparison of cardiac MRI features of fibrosis and strain for early cardiac dysfunction assessment in patients with systemic lupus erythematosus and Sjögren's syndrome.

  Lupus Sci Med, Sept 2026

• Correlation between perivascular spaces and clinical features in patients with rheumatoid arthritis.

  Clin Rheumatol, Sept 2026

• Peripheral bone erosion and atlantoaxial instability as factors associated with pannus formation in rheumatoid arthritis: a cross-sectional risk stratification study.

  Clin Rheumatol, Aug 2026

• Characteristic central nervous system fingerprints and related molecular signatures in difficult-to-treat rheumatoid arthritis.

  J Neuroinflammation, Aug 2026

• Ultra-high-field 5 T MRI for parotid gland assessment in Sjögren's syndrome: Improved image quality and reliable fat fraction quantification.

  Magn Reson Imaging, Aug 2026

• Predicting the risk of bone erosion in rheumatoid arthritis using a SHAP-based interpretable machine learning model.

  Clin Rheumatol, Jul 2026

• Zero Time-to-Echo Imaging of the Hand and Wrist in Rheumatoid Arthritis Patients.

  J Magn Reson Imaging, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.